|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquisition
|
gptkb:Medi_Gene_AG
gptkb:Calithera_Biosciences
|
|
gptkbp:ceo
|
Herbert W. (Herb) Hooper
|
|
gptkbp:clinical_trial
|
Phase 1
Phase 2
Phase 3
|
|
gptkbp:conducts_research_on
|
gptkb:David_A._Hyman
|
|
gptkbp:focus
|
oncology
autoimmune diseases
inflammation
|
|
gptkbp:founded
|
gptkb:1991
|
|
gptkbp:founder
|
gptkb:Paul_Friedman
|
|
gptkbp:head_of_commercial
|
gptkb:Cynthia_L._Smith
|
|
gptkbp:head_of_state
|
gptkb:M._Scott_Mc_Kinley
|
|
gptkbp:headquarters
|
gptkb:Wilmington,_Delaware
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Incyte
|
|
gptkbp:market_cap
|
$10 billion (2021)
|
|
gptkbp:number_of_employees
|
~1,500
|
|
gptkbp:partnership
|
gptkb:Takeda_Pharmaceutical_Company
gptkb:Astra_Zeneca
gptkb:Sanofi
gptkb:Boehringer_Ingelheim
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
gptkb:Merck_&_Co.
gptkb:Roche
gptkb:Amgen
gptkb:Gilead_Sciences
gptkb:Eli_Lilly_and_Company
gptkb:Abb_Vie
gptkb:Novartis
|
|
gptkbp:related_products
|
gptkb:Iclusig
gptkb:Jakafi
gptkb:Pemazyre
|
|
gptkbp:research_focus
|
biomarkers
drug discovery
genomics
|
|
gptkbp:revenue
|
$1.5 billion (2020)
|
|
gptkbp:stock_exchange
|
gptkb:NASDAQ
|
|
gptkbp:stock_symbol
|
gptkb:INCY
|
|
gptkbp:subsidiary
|
gptkb:Incyte_Biosciences
gptkb:Incyte_Europe
Incyte Japan
|
|
gptkbp:bfsParent
|
gptkb:Agenus_Inc.
|
|
gptkbp:bfsLayer
|
5
|